Ken Griffin Karyopharm Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 79,600 shares of KPTI stock, worth $57,312. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,600
Previous 29,800
167.11%
Holding current value
$57,312
Previous $44,000
56.82%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding KPTI
# of Institutions
120Shares Held
64.9MCall Options Held
500KPut Options Held
99K-
Vanguard Group Inc Valley Forge, PA7.65MShares$5.51 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.1MShares$3.67 Million0.56% of portfolio
-
Eversept Partners, LP New York, NY4.99MShares$3.59 Million0.33% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.32MShares$3.11 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.17MShares$3 Million0.0% of portfolio
About Karyopharm Therapeutics Inc.
- Ticker KPTI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,806,600
- Market Cap $57.5M
- Description
- Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...